Teva Pharmaceutical Industries (TEVA) Other Working Capital Changes (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has 18 years of Other Working Capital Changes data on file, last reported at $19.0 million in Q2 2026.

• Quarterly Other Working Capital Changes fell 81.9% year-over-year to $19.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$49.0 million (down 181.67% YoY) and the FY2025 annual result came in at $81.0 million, down 85.54% from the prior year.
• Other Working Capital Changes improved to $19.0 million in Q2 2026, from -$54.0 million in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of $700.0 million in Q1 2025 to a low of -$1.9 billion in Q4 2023.
• A 5-year average of -$171.2 million and a median of -$220.5 million in 2023 frame the typical range for Other Working Capital Changes.
• Annual changes were most pronounced in 2022 — Other Working Capital Changes sank 3666.67% — and 2024, when it jumped 5033.33%.
• Tracing TEVA's Other Working Capital Changes over 5 years: stood at $26.0 million in 2022, then jumped by 65.38% to $43.0 million in 2023, then slumped by 186.05% to -$37.0 million in 2024, then fell by 10.81% to -$41.0 million in 2025, then surged by 146.34% to $19.0 million in 2026.
• The last three Other Working Capital Changes figures came in at $19.0 million (Q2 2026), -$54.0 million (Q1 2026), and -$41.0 million (Q4 2025), per Business Quant data.